Key result
Higher second-trimester urinary 11-dehydro-TXB2 predicts preeclampsia in high-risk women despite low-dose aspirin.
Why the study?
Low-dose aspirin prevents pre-eclampsia but exhibits interindividual variability in responsiveness, and clinical predictors and biomarkers of pre-eclampsia in high-risk patients are needed.
Does urinary 11-dehydro-thromboxane B2 predict the development of preeclampsia in high-risk pregnant women treated with low-dose aspirin?
Does urinary 11-dehydro-thromboxane B2 predict the development of preeclampsia in high-risk pregnant women treated with low-dose aspirin?
Residual thromboxane-dependent platelet activation during the second trimester may predict the occurrence of preeclampsia in high-risk pregnant women despite low-dose aspirin prophylaxis.
May flag preeclampsia risk despite aspirin; hypothesis-generating and should not yet change practice.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Simeone et al. (2025) studied this question. In high-risk pregnant women on low-dose aspirin, higher urinary 11-dehydro-TXB2 in the second trimester predicted preeclampsia development despite aspirin prophylaxis (p=0.035).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: